...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Biological chemistry >Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential.
【24h】

Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential.

机译：分泌性白蛋白蛋白酶抑制剂和肺表面活性剂是抵抗气道中甲型流感病毒感染的主要防御手段，上调其水平的化学试剂可能具有治疗潜力。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Influenza A virus (IAV) is one of the most common infectious pathogens in humans. Entry of this virus into cells is primarily determined by host cellular trypsin-type processing proteases, which proteolytically activate viral membrane fusion glycoprotein precursors. Human IAV and murine parainfluenza virus type 1 Sendai virus are exclusively pneumotropic, and the infectious organ tropism of these viruses is determined by the susceptibility of the viral envelope glycoprotein to cleavage by proteases in the airway. Proteases in the upper respiratory tract are suppressed by secretory leukoprotease inhibitor, and those in the lower respiratory tract are suppressed by pulmonary surfactant, which by adsorption inhibits the interaction between the proteases and viral membrane proteins. Although the protease activities are predominant over the activities of inhibitory compounds under normal airway conditions, intranasal administration of inhibitors was able to significantly suppress multi-cycles of viral replication in the airway. In addition, we identified chemical agents that could act as defensive factors by up-regulating the levels of the natural inhibitors and immunoglobulin A (IgA) in airway fluids. One of these compounds, ambroxol, is a mucolytic and anti-oxidant agent that stimulates the release of secretory leukoprotease inhibitor and pulmonary surfactant in the early phase, and IgA in the late phase of infection at an optimal dose, i.e. a dose sufficient to inhibit virus proliferation and increase the survival rate of animals after treatment with a lethal dose of IAV. Another agent, clarithromycin, is a macrolide antibiotic that increases IgA levels through augmentation of interleukin-12 levels and mucosal immunization in the airway. In addition to the sialidase inhibitors, which prevent the release of IAV from infected cells, inhibitors of the processing proteases and chemical agents that augment mucosal immunity and/or levels of the relevant defensive compounds may also ultimately prove to be useful as new anti-influenza agents.
机译：甲型流感病毒（IAV）是人类最常见的传染性病原体之一。该病毒进入细胞的过程主要由宿主细胞胰蛋白酶型加工蛋白酶决定，该蛋白酶通过蛋白水解激活病毒膜融合糖蛋白前体。人类IAV和1型鼠源副流感病毒仙台病毒完全是嗜气性的，这些病毒的感染器官嗜性取决于病毒包膜糖蛋白对气道中蛋白酶裂解的敏感性。上呼吸道中的蛋白酶被分泌性白蛋白蛋白酶抑制剂抑制，下呼吸道中的蛋白酶被肺表面活性剂抑制，肺表面活性剂通过吸附抑制蛋白酶和病毒膜蛋白之间的相互作用。尽管蛋白酶活性在正常气道条件下比抑制性化合物的活性更重要，但鼻内施用抑制剂能够显着抑制气道中病毒复制的多个周期。此外，我们确定了可以通过上调气道液中天然抑制剂和免疫球蛋白A（IgA）的水平来充当防御因素的化学剂。这些化合物之一，氨溴索，是一种粘液溶解和抗氧化剂，可以以最佳剂量（即足以抑制感染的剂量）在感染的初期刺激分泌型白蛋白蛋白酶抑制剂和肺表面活性剂的释放，并在感染的后期刺激IgA的释放。致死剂量的IAV处理后，病毒可增殖并提高动物的存活率。另一种药物克拉霉素是一种大环内酯类抗生素，可通过增加白介素12水平和气道粘膜免疫来增加IgA水平。除了可以阻止IAV从感染细胞中释放的唾液酸酶抑制剂外，加工蛋白酶抑制剂和增强粘膜免疫力和/或相关防御性化合物水平的化学试剂也可能最终被证明可用作新型抗流感药代理商。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号